U3-1287

DRUG2 trials

Sponsors

Daiichi Sankyo

Conditions

Metastatic Breast CancerNSCLC (Advanced Non-small Cell Lung Cancer)

Phase 1

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

CompletedNCT01211483

Daiichi SankyoNSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2010-09-30End: 2013-11-23Updated: 2021-06-16

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

TerminatedNCT01512199

Daiichi SankyoMetastatic Breast Cancer

Start: 2011-11-30End: 2015-01-28Updated: 2017-10-18

Related Papers

Soluble heregulin, HER3 ligand, to predict the efficacy of anti-HER3 antibody patritumab combination with erlotinib in randomized phase II study, HERALD, for non-small cell lung cancer.

Journal of Clinical Oncology2016-05-204 citations

Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs).

Journal of Clinical Oncology2014-05-2021 citations

Identification of a predictive biomarker for patritumab (P), an anti-HER3 monoclonal antibody, in advanced NSCLC.

Journal of Clinical Oncology2014-05-201 citations

Population pharmacokinetic (PK) analysis from phase 1 and 2 studies of the HER3 inhibitor patritumab in patients with advanced non-small cell lung cancer (NSCLC) or solid tumors.

Journal of Clinical Oncology2014-05-20